The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Subscribe To Our Newsletter & Stay Updated
